Differential in vitro response to octreotide and pasireotide in normal and tumoral primary pituitary cell cultures

Authors:
  • MGManuel David Gahete
    Manuel David Gahete
  • LJLuis Jimenez-Reina
    Luis Jimenez-Reina
  • EREsther Rivero-Cortes
    Esther Rivero-Cortes
  • LLLaura Maria Lopez-Sanchez
    Laura Maria Lopez-Sanchez
  • MGMaria Angeles Galvez
    Maria Angeles Galvez
  • LDla Riva Andres de
    la Riva Andres de
  • PBPedro Benito-Lopez
    Pedro Benito-Lopez
  • EVEva Venegas-Moreno
    Eva Venegas-Moreno
  • JAJapon Miguel Angel
    Japon Miguel Angel
  • AMAlberto Moreno
    Alberto Moreno
  • JGJuan Antonio Garcia-Arnes
    Juan Antonio Garcia-Arnes

Abstract
Somatostatin analogs (SSA) are a first-line treatment for pituitary adenomas (PA). Indeed, multi-receptor targeting SSA such as octreotide and pasireotide are being successfully used to control hormone secretion and/or tumor growth. Unfortunately, many PA escape from SSA-therapy, which could be related to somatostatin receptor (sst) presence, abundance, availability and/or signaling. In order to better define the molecular/cellular features associated to octreotide and pasireotide responsiveness, we have established a reliable methodology to evaluate, in parallel, the in vitro response to octreotide and pasireotide using primary PA cultures by assessing sst-signaling (free-cytosolic (Ca2+) kinetics) and secretory and proliferative responses. In addition, expression of pituitary hormones and ssts using RT-PCR and, hormonal secretion by immuno-blotting was assessed. A total of 44 samples (16 somatotropinomas, 6 corticotropinomas, 5 prolactinomas, 15 non-functioning PA (NFPA) and 2 normal pituitaries) were evaluated. Octreotide and pasireotide treatment decrease (Ca2+) kinetics in 13/16 and 7/16 somatotropinomas respectively; while both SSA similarly inhibited GH secretion and proliferation. Inhibition of (Ca2+) kinetics in response to octreotide and pasireotide were observed in 2/6 and 4/6 corticotropinomas, although it only occurs in a small proportion of cells, whereas ACTH release was not significantly affected. In prolactinomas, only octreotide inhibited (Ca2+) kinetics. In NFPA, both SSA moderately decreased (Ca2+) kinetics (few responsive PA, with moderate inhibition and small proportion of responsive cells), while surprisingly, both SSA stimulated cell proliferation in a considerable proportion of PA. Finally, octreotide did not alter (Ca2+) kinetics in normal pituitary cultures while, pasireotide exerted a faint inhibitory response. The differential response to octreotide and/or pasireotide could not be explained by significant differences in sst-expression pattern between responsive and non-responsive PA. Altogether, our data indicate the existence of a differential in vitroresponse to octreotide and pasireotide in normal and tumoral primary pituitary cell cultures and therefore, further studies are necessary to unveil the key factors involved in this differential responsiveness to SSA.